ATS PITB Assembly
- Drs. Green, Devarajan, Swenson, Losier, and Gu discuss non-cystic #bronchiectasis emphasising the importance of mucus, from biochemical properties to clinical practice. A must view for those interested in #bronchiectasis research. #Chest #ATS www.chestnet.org/guidelines-a...
- 🔥🔥🔥 HOT OF THE PRESS!🔥🔥🔥 Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial - The Lancet Infectious Diseases www.thelancet.com/journals/lan...
- 🚨Don’t miss the deadline—vote now for your Assembly leaders! site.thoracic.org/membership/a...
- This retrospective cohort study assessed nirmatrelvir–ritonavir (NMVr) effectiveness in severe COVID-19 using real-world data. 🦠🧫 Results showed NMVr therapy was associated with lower risks of intubation and in-hospital mortality. link.springer.com/article/10.1...
- Hein et al. investigated the association between vitamin D status and mortality in patients hospitalized with CAP 💊🫁 Results suggested a higher risk of 90- and 180-day mortality among those with vitamin D deficiency. academic.oup.com/ofid/article...
- Reposted by ATS PITB Assembly[Not loaded yet]
- 🫁Sensitization to recombinant Aspergillus fumigatus (rAsp f) is a key trait in bronchiectasis. This multicenter study across four countries links rAsp f allergen responses to severe exacerbations, especially in those with <3 events/year. #CHESTjournal journal.chestnet.org/article/S001...
- 🧫 In this ENIRRI secondary analysis of 1,059 ICU patients with nosocomial respiratory infections, P. aeruginosa accounted for 14.5% of cases and was strongly associated with COPD GOLD D, autoimmune disease, chronic kidney disease, and early acute kidney injury. 🫁 buff.ly/HuqtpoR
- 🧪Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Ian Galbreath, MD!🔬 Dr. Galbreath's research has focused on early life viral infections 🦠 and development of asthma. 🧫 When he is not seeing patients, he is an avid runner! 🏃 🥼
- 🫁Latest in implementation science, mHealth for TB + smokers: Cluster RCT in Pakistan (n=1080) found daily→monthly text messages tripled biochemically confirmed 6‑mo abstinence (41.7% vs 15.3%; RR≈3.0) without harming TB outcomes!📱 jamanetwork.com/journals/jam...
- New in Nature Medicine: Modeling of 6.8M TB notifications from 111 LMICs shows that scaling up PCR-based diagnostics mainly reduces missed TB (false negatives), but has a much smaller impact on false-positive diagnoses driven by clinical judgment alone. t.co/RheMwTphqK
- ✨ Recently published: Among adults aged 65–79 in the GALFLU trial (n=103,169), the high-dose inactivated influenza vaccine appeared to be associated with fewer hospitalizations for influenza or PNA compared with the standard dose. #NEJM www.nejm.org/do/10.1056/N...
- ✨ Recently published in AJRCCM: Data from the EMBARC-BRIDGE study show a key link between the upper-airway microbiome and clinical outcomes in patients with bronchiectasis. www.atsjournals.org/doi/epdf/10....
- 🧪Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Pramod Bhattarai!🔬 Dr. Bhattarai serves rural and underserved communities and his research focuses on health disparities, particularly in people living with HIV. 🧫 When out of the clinic, he enjoys coin collecting 🪙 and hiking 🥾!
- In the SONIA trial, adjunct low-dose glucocorticoid use in patients hospitalized with CAP in a low-resource setting was associated with lower 30-day all-cause mortality compared with standard care. #NEJM www.nejm.org/doi/full/10....
- A cohort study of 28 million individuals aged 18–59 found no increased risk of 4-year all-cause mortality among those vaccinated against COVID-19. #JAMA jamanetwork.com/journals/jam...
- Soulmate et al.’s meta-analysis showed, with moderate certainty of evidence, that adjunctive low-dose, short-course corticosteroids probably reduce short-term mortality in both severe PNA and ARDS. pubmed.ncbi.nlm.nih.gov/41325621/
- 📢📢📢Less than a week left! Learn the latest on HIV-associated lung disease in the upcoming 🌲PINE Webinar on #worldaidsday December 1st! @idsainfo.bsky.social @atscommunity.bsky.social @btsrespiratory.bsky.social @theunion.org Sign up here: thoracic.zoom.us/webinar/regi...
- 🔥Mark your calendars!🔥 @ATS_PITB is hosting a🌲PINE🌲Webinar on HIV-associated lung disease 🫁 Case-based discussion, with🌍global experts! 📅 Monday, December 1st 3PM ET 🗒️Register Here: thoracic.zoom.us/webinar/regi... #TB @ATS_Assemblies @IDSAInfo @TheUnion_TBLH @BTSrespiratory
- Among mechanically ventilated patients, selective digestive decontamination did not reduce in-hospital mortality compared with standard care. #NEJM #PITB #SuDDICU www.nejm.org/doi/full/10....
- Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia publications.ersnet.org/content/erj/...
- 🚨 New 2025 ERS guidelines for the management of adult bronchiectasis! Takeaway: Recommend to offer long-term macrolides to patients at high risk of exacerbations. High-risk features include P. aeruginosa infection, COPD, PCD, RA, and sputum purulence. doi.org/10.1183/1399...
- 🚨New 2025 ERS guidelines for the management of adult bronchiectasis! Key takeaway: Recommend not offering long-term ICS to patients with bronchiectasis who do not have coexisting asthma or COPD. doi.org/10.1183/1399...
- 🔥Mark your calendars!🔥 @ATS_PITB is hosting a🌲PINE🌲Webinar on HIV-associated lung disease 🫁 Case-based discussion, with🌍global experts! 📅 Monday, December 1st 3PM ET 🗒️Register Here: thoracic.zoom.us/webinar/regi... #TB @ATS_Assemblies @IDSAInfo @TheUnion_TBLH @BTSrespiratory
- 🚨New 2025 ERS guidelines for the management of adult bronchiectasis! Key update: Recommend offering long‑term inhaled antibiotics to patients at high risk of exacerbations and with chronic Pseudomonas aeruginosa infection despite standard care. publications.ersnet.org/content/erj/...
- 💫In this randomized, phase 2 clinical trial, telacebec demonstrated antimycobacterial activity over 14 days in patients with smear-positive pulmonary TB. #AJRCCM doi.org/10.1164/rccm...
- Reposted by ATS PITB Assembly[Not loaded yet]
- Reposted by ATS PITB Assembly[Not loaded yet]
- 🔥🔥🔥 Hot of the press: European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis publications.ersnet.org/content/erj/... #Bronchiectasis @atscommunity.bsky.social @btsrespiratory.bsky.social
- 🧪Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Kevin Guzman!🔬 Dr. Guzman is working to improve outcomes in people living with HIV and TB. 🧫
- ✨ Published in AJRCCM: A comprehensive analysis of NTM-related mortality in the US reveals a rise over the past two decades, with notable disparities across age, race, gender, and geography. www.atsjournals.org/doi/epdf/10....
- Recently published in AJRCCM: A systematic review and meta-analysis of 6,668 household contacts of MDR-TB found that isoniazid was effective in preventing incident TB, particularly in high-burden countries. #TB #globalhealth #StopTB www.atsjournals.org/doi/epdf/10....
- 🔥Mark your calendars!🔥 @ats-pitb.bsky.social is hosting a🌲PINE🌲Webinar on Post-TB Lung Disease 🫁 Case-based discussion, diagnosis & treatment with 🌍 global experts! 📅 Tue Oct 28 10AM ET 🗒️Register Here: bit.ly/47X6auu #TB @atscommunity.bsky.social @theunion.org @btsrespiratory.bsky.social
- Great honor to welcome Dr. Charles Dela Cruz, past @ats-pitb.bsky.social Chair, to @tulanemedicine.bsky.social today! He is giving an outstanding talk on COVID-19 and interferons—sharing deep insights into pathogenesis and host responses. #COVID19 #Interferons #ATS
- Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial - The Lancet Respiratory Medicine www.thelancet.com/journals/lan...
- 🚨 ATS Workshop Report on non-invasive sampling of the lower respiratory tract: Experts highlight how to tailor your testing and make non-invasive testing fast, reproducible, and scalable. #PulmCCM #ATSworkshop buff.ly/i2qobaA
- 🚨 New 2025 ATS guidelines on community-acquired pneumonia! Key change: Empiric antibiotics are suggested for adults hospitalized with clinical and imaging evidence of CAP—whether non-severe or severe—who test positive for a respiratory virus. doi.org/10.1164/rccm...
- Reposted by ATS PITB Assembly[Not loaded yet]
- 🌟 Brensocatib: first FDA-approved therapy for bronchiectasis. Key takeaways! First DPP-1 inhibitor for non-CF bronchiectasis & neutrophil-mediated disease. Effective across key subgroups: macrolide users, varying eosinophil counts, adolescents. www.nejm.org/doi/full/10....
- 🚨 New 2025 ATS guidelines on community-acquired pneumonia! Key points: For stable adults with outpatient CAP, <5 days of antibiotics are recommended (minimum duration: 3 days). Systemic corticosteroids for adults hospitalized with severe CAP. doi.org/10.1164/rccm...
- AJRCCM: Results from a randomized, placebo-controlled Phase II clinical trial evaluating the optimal dose, acceptable safety, and tolerability of levofloxacin as part of a multidrug TB regimen. doi.org/10.1164/rccm...
- 🚨 New 2025 ATS guidelines on community-acquired pneumonia! Key changes: Lung ultrasound now an evidence-based alternative to chest X-ray for diagnosis No antibiotics for outpatients with no comorbidities and a positive viral test doi.org/10.1164/rccm...
- Reposted by ATS PITB Assembly[Not loaded yet]
- Reposted by ATS PITB Assembly[Not loaded yet]
- A timely human H5N1 bird flu update: 70 US cases from March 2024-May 2025, mostly mild but 4 hospitalized, 1 death. Nearly all linked to exposure to dairy cows or poultry. No evidence of human-to-human transmission. buff.ly/3nLif75
- www-atsjournals-org.ezproxy.med.nyu.edu/doi/10.1164/... Telacebec is a novel, first-in-class agent targeting mycobacterial cellular energy production with activity against M. tuberculosis, M. leprae, and M. ulcerans, representing a new strategy for treating diseases associated with these pathogens.
- thorax.bmj.com/content/80/S... The BTS Clinical Statement on Aspergillus-related chronic lung disease sets out best practice in the diagnosis and management of chronic fungal lung disease.
- www.nature.com/articles/s41... Results from an open-label, multi-arm phase 1 clinical trial evaluating an inhaled aerosol COVID-19 vaccine are promising, representing a new vaccine strategy that aims to induce respiratory mucosal immunity.
- www.nejm.org/doi/full/10.... FDA approves brensocatib for the tx of bronchiectasis: "... [o]nce-daily tx with brensocatib...led to a lower annualized rate of pulmonary exacerbations than placebo, and the decline in FEV1 was less with the 25-mg dose of brensocatib than with placebo."
- pmc.ncbi.nlm.nih.gov/articles/PMC... TB survivors are at risk of lifelong disability, reduced economic productivity, and a range of physical, psychological, and social sequalae.
- www.atsjournals.org/doi/abs/10.1... ✨NEW✨ATS Guidelines for Community-Acquired Pneumonia-addresses lung ultrasound for diagnosis, empiric antibacterial therapy if a test for a respiratory virus is positive, antibiotic duration, and the use of systemic corticosteroids.
- publications.ersnet.org/content/erjo... TB has negative impacts on health-related quality of life-e.g., anxiety and depression are common in people with TB. Consider routine screening for depression and anxiety, with referral to psychiatry if necessary, to improve disease outcomes and QOL.
- pmc.ncbi.nlm.nih.gov/articles/PMC... Practice alert! Providers should submit sputum in addition to urinary antigen testing when diagnosing legionella pneumonia.
- pubmed.ncbi.nlm.nih.gov/40601818/ Empiric broad-spectrum abx use in moderately immunocompromised patients with CAP not associated with mortality, but was associated with harm (30-day readmission, transfer to ICU, longer duration of hospitalization).
- 📢📢📢 Don't miss the excellent webinar from our pediatric ATS colleagues on the important topic of pediatric TB! Info below. #STOPTB --- @ATSPeds VIPPN case series on Challenges in Diagnosis of Childhood Tuberculosis in Low Resource Settings August 7th at 1pm ET Register here: shorturl.at/Gyqop
